Table 2.
Summary of included studies related to IL-10 and IL-13 and OSCC.
| Cytokine Biomarker | Matrix | Validation Methods | Biological Sample | Results | p Value | Reference |
|---|---|---|---|---|---|---|
| IL-10 | Saliva | MILLIPLEX (4-plex) Human Cytokine/Chemokine Assay kit | Control (n = 33) OSCC (n = 30) |
IL-10 levels in OSCC individuals were found to be higher than the healthy counterparts and could be utilized as diagnostic and prognostic markers in OSCC patients. | 0.004 | [67] |
| IL-13 | Saliva | MILLIPLEX (4-plex) Human Cytokine/Chemokine Assay kit | Control (n = 33) OSCC (n = 30) |
IL-13 levels were elevated in the OSCC group in comparison to the healthy one. | 0.010 | [67] |
| IL-10 | Saliva Serum Tissue |
ELISA IHC |
Control (n = 24) OSCC (n = 30) |
IL-10 tissue expression was statistically significant higher in the OSCC group, but no statistical differences were observed in serum or salivary levels. | 0.001 | [72] |
| IL-10 | Saliva Serum Tissue |
ELISA IHC |
Control (n = 5) OSCC (n = 20) | Il-10 levels in serum had no significant difference in the OSCC and the controls; OSCC biopsies indicated immunoreactivity to IL-10, while normal samples were immune-negative. | <0.05 | [73] |
| IL-10 | Saliva Serum |
ELISA | Control (n = 40) OSCC (n = 78) |
IL-10 level was higher in the OSCC group than in controls in the salivary and serum samples. | <0.05 | [74] |